# Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer

> **NCT00278460** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 49 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00278460
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2006-02
- **Final completion:** 2007-09
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2017-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278460, "Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00278460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*